NewBridge Pharmaceutical CEO Joe Henein On Licensing And Commercializing Drugs In The Middle East: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
With nearly 30 years of experience under his belt, veteran pharmaceutical executive Joe Henein previously served as the regional managing director for Wyeth Middle East before joining Dubai-based NewBridge Pharmaceuticals as its chief executive officer. NewBridge is a venture-backed specialty pharma company, jointly invested by Burrill & Company and Kuwait Life Science Company, a subsidiary of National Technology Enterprises Company of Kuwait. The company announced last September the close of $12 million in Series B financing, bringing the total amount raised to date to $16 million.